Independent Investors Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 81,316 shares of the company’s stock after selling 1,769 shares during the quarter. Johnson & Johnson accounts for about 3.9% of Independent Investors Inc.’s holdings, making the stock its 2nd biggest holding. Independent Investors Inc.’s holdings in Johnson & Johnson were worth $11,861,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Arjuna Capital boosted its position in shares of Johnson & Johnson by 20.1% during the second quarter. Arjuna Capital now owns 23,969 shares of the company’s stock worth $3,338,000 after purchasing an additional 4,017 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Johnson & Johnson by 86.7% during the second quarter. Jacobs Levy Equity Management Inc. now owns 39,160 shares of the company’s stock worth $5,454,000 after purchasing an additional 18,180 shares in the last quarter. National Pension Service boosted its position in shares of Johnson & Johnson by 5.5% during the second quarter. National Pension Service now owns 2,597,910 shares of the company’s stock worth $361,837,000 after purchasing an additional 135,998 shares in the last quarter. A.R.T. Advisors LLC boosted its position in shares of Johnson & Johnson by 119.4% during the second quarter. A.R.T. Advisors LLC now owns 31,610 shares of the company’s stock worth $4,403,000 after purchasing an additional 17,200 shares in the last quarter. Finally, STA Wealth Management LLC boosted its position in shares of Johnson & Johnson by 240.9% during the second quarter. STA Wealth Management LLC now owns 10,823 shares of the company’s stock worth $1,507,000 after purchasing an additional 7,648 shares in the last quarter. Hedge funds and other institutional investors own 67.28% of the company’s stock.
JNJ opened at $147.01 on Thursday. The stock has a market capitalization of $385.62 billion, a P/E ratio of 17.97, a P/E/G ratio of 2.36 and a beta of 0.71. Johnson & Johnson has a 12 month low of $125.00 and a 12 month high of $147.84. The firm’s fifty day simple moving average is $143.07 and its 200 day simple moving average is $134.77. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 EPS. On average, equities research analysts predict that Johnson & Johnson will post 8.66 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a $0.95 dividend. The ex-dividend date is Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.58%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
In other Johnson & Johnson news, Director Hubert Joly purchased 5,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $141.28 per share, with a total value of $706,400.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $706,400. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now directly owns 51,736 shares in the company, valued at $7,298,397.52. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.
A number of equities analysts have recently weighed in on JNJ shares. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Friday, October 11th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective on the stock in a research report on Wednesday, December 18th. Raymond James cut their price objective on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $145.00 to $170.00 in a research report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $159.33.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: How Do I Invest in Dividend Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.